SCHEMBL24253549

SCHEMBL24253549

COC(=O)c1nc(Cl)cc(-n2cc(C(F)(F)F)cn2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 3/20 0.36
GPR35 Q9HC97 2/20 0.36
MAPK1 P28482 1/20 0.36
LMNA P02545 2/20 0.35
GAA P10253 1/20 0.35
ACACB O00763 1/20 0.35
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
GABRB2 P47870 1/20 0.34
GABRA4 P48169 1/20 0.34
GABRE P78334 1/20 0.34
GABRA6 Q16445 1/20 0.34
GABRG1 Q8N1C3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24253730 0.76 GABRB3 (0.38) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL31705370 0.73 SLC34A1 (0.42) NOTUMMAPK1LMNAEGLN1MAPT
SCHEMBL31706156 0.73 SLC34A1 (0.42) NOTUMMAPK1LMNAEGLN1MAPT
SCHEMBL24253899 0.73 CYP2D6 (0.41) LMNAGABRPGABRDGABRA1GABRB1
SCHEMBL7468057 0.73 NOTUM (0.43) NOTUMLMNAGAAACACBEGLN1
SCHEMBL11300906 0.72 KDM4E (0.49) NOTUMMAPK1SMN1; SMN2KDM4EALDH1A1
SCHEMBL30767554 0.72 CFTR (0.43) NOTUMLMNAGAAMAPTCFTR
SCHEMBL30767491 0.71 GCG (0.47) MAPK1LMNAEGLN1MAPTSMN1; SMN2
SCHEMBL31431035 0.71 GCGR (0.37) NOTUMLMNAEGLN1MAPTCFTR
SCHEMBL5380843 0.71 PDE10A (0.39) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 NOTUM 3732/4885GPR35 1370/4885MAPK1 3459/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 NOTUM 3732/4885GPR35 1370/4885MAPK1 3459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.